Nevada
|
0-30379
|
88-0425691
|
(State or other jurisdiction of Incorporation)
|
(Commission File Number)
|
(IRS Employer Identification Number)
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
ITEM 7.01. |
REGULATION FD DISCLOSURE.
|
ITEM 9.01. |
FINANCIAL STATEMENTS AND EXHIBITS
|
99.1 |
Press Release, dated May 24, 2018, titled “Chembio Diagnostics Announces Agreement with Bio-Manguinhos to Commercialize Point-of-Care Tests for Dengue, Zika and
Chikungunya in Brazil”.
|
May 25, 2018
|
Chembio Diagnostics, Inc.
|
|
By:
|
/s/ John J. Sperzel III
|
|
John J. Sperzel III
|
||
Chief Executive Officer
|
Exhibit
Number
|
Description
|
Press Release, dated May 24, 2018, titled “Chembio Diagnostics Announces Agreement with Bio-Manguinhos to Commercialize Point-of-Care Tests for
Dengue, Zika and Chikungunya in Brazil”.
|
· |
Development of new point-of-care DPP® tests for Dengue, Zika, and Chikungunya as both standalone and multiplex tests.
|
· |
Clinical testing of the new DPP® tests and DPP® Micro Reader in numerous regions, including the United States, Africa, Latin America and Southeast Asia.
|
· |
Regulatory approval for the DPP® Zika System, including Brazil Agência Nacional de Vigilância Sanitária approval, U.S. Food and Drug Administration Emergency Use
Authorization, and CE mark.
|
· |
A conditional agreement from UNICEF for purchases of the Company’s DPP® Zika System, which includes a purchase commitment of $1.5 million and
possible additional purchases of up to $3.4 million.
|